How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?

Click to increase image sizeClick to decrease image size

Disclosure statement

Dr. Flowers was an investigator on GO29365. No potential conflict of interest was reported by the author(s).

Additional information

Funding

CRF is the CPRIT Scholar of Cancer Research. The project described was supported in part by CRF's K24 CA208132 award for mentored patient-oriented research in lymphoma from the National Cancer Institute and CPRIT Award RR190079. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.